learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultslearn multipeptides
learn PTT-6®
learn PTD-DBM
learn Iodopropynyl Butylcarbamate
Research
5 / 1000+ results
research Optimization of the method for the culture of melanocyte precursors from hair follicles and their activation by 1,25-dihydroxyvitamin D3
1,25-dihydroxyvitamin D3 helps melanocyte precursors from hair follicles grow and produce melanin, aiding vitiligo treatment understanding.
research Cutaneous Manifestations of Mucopolysaccharidoses
People with Mucopolysaccharidoses often have skin problems like thick skin and extra hair, and recognizing these can help diagnose and treat the condition early.
research Dwarf planet Ceres and the ingredients of life
The Dawn spacecraft found that Ceres has complex organic molecules and a lot of water ice, hinting it might support life.
research Abstracts
Get head MRI for babies with achondroplasia early, use free immunoglobulin light chains to detect certain neurodevelopmental disorders, and video calls work for speech therapy in patients with facial anomalies.
research Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications
Improving artificial vascular grafts requires better materials and surface designs to reduce blood clotting and support blood vessel cell growth.
Community Join
5 / 1000+ resultscommunity Testosterone before and after take fin/dut
User experienced 100% testosterone increase after using Finasteride and Dutasteride for hair loss. Some users discuss potential side effects and reasons for the increase.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.